At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Hendrik-Tobias Arkenau, MD, PhD, of Sarah Cannon Research Institute, London, UK, discusses the results of the phase 3 COMBI-d trial which compared the combination of dabrafenib and trametinib with dabrafenib and placebo as first-line therapy in patients with unresectable or metastatic BRAF V600E/K mutation-positive cutaneous melanoma.
Phase 3 COMBI-d trial of dabrafenib plus trametinib in metastatic
23rd July 2015
Oncology
Please rate the quality of this content
We are sorry that this content was not interesting for you!
Let us improve this content!
Tell us how we can improve this content?